Literature DB >> 8032243

Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins.

A G Mosser1, D A Shepard, R R Rueckert.   

Abstract

The WIN drugs and similar hydrophobic compounds that insert into the capsid of picornaviruses have been shown to block viral uncoating. In some of the human rhinoviruses they also block attachment of virus to cells. Spontaneously occurring drug-resistant mutants of human rhinovirus 14 and poliovirus type 3 were selected for their ability to make plaques in the presence of the selecting drug. The HRV-14 mutants either prevented drug binding or allowed the virus to attach to cells in the presence of drug. About two thirds of the poliovirus mutants were dependent on the presence of drug for plaque formation. In single cycle growth curves, drug was not required for the formation of drug-dependent progeny virus. However, progeny virus grown without drug never accumulated outside of cells, thus making the formation of plaques impossible. This behavior was apparently caused by the extreme thermolability of these mutants. In the absence of drug, heating to 37 degrees C rapidly converted them to non-infectious particles with a sedimentation coefficient of 135S.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032243     DOI: 10.1007/978-3-7091-9326-6_12

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN: 0939-1983


  3 in total

1.  Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.

Authors:  Hong-Mei Liu; Jason A Roberts; Deborah Moore; Barbara Anderson; Mark A Pallansch; Daniel C Pevear; Marc S Collett; M Steven Oberste
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

2.  Structural analysis of human rhinovirus complexed with ICAM-1 reveals the dynamics of receptor-mediated virus uncoating.

Authors:  Li Xing; José M Casasnovas; R Holland Cheng
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

3.  Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.

Authors:  Anna L Salvati; Alessandra De Dominicis; Sabrina Tait; Andrea Canitano; Armin Lahm; Lucia Fiore
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.